H
Hans-Joachim Lueck
Researcher at Praxis
Publications - 19
Citations - 881
Hans-Joachim Lueck is an academic researcher from Praxis. The author has contributed to research in topics: Epirubicin & Breast cancer. The author has an hindex of 9, co-authored 18 publications receiving 680 citations.
Papers
More filters
Journal ArticleDOI
Triple-negative and HER2-overexpressing breast cancers exhibit an elevated risk and an earlier occurrence of cerebral metastases
Florian Heitz,Philipp Harter,Hans-Joachim Lueck,Annette Fissler-Eckhoff,F Lorenz-Salehi,Stefanie Scheil-Bertram,Alexander Traut,Andreas du Bois +7 more
TL;DR: Patients with triple-negative or HER2-positive BC have a higher risk for CM compared with patients bearing the ER+/HER2- phenotype and develop CM earlier in the course of disease.
Journal ArticleDOI
Addition of Epirubicin As a Third Drug to Carboplatin-Paclitaxel in First-Line Treatment of Advanced Ovarian Cancer: A Prospectively Randomized Gynecologic Cancer Intergroup Trial by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group and the Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens
Andreas du Bois,Béatrice Weber,Justine Rochon,Werner Meier,Alain Goupil,S. Olbricht,Jean-Claude Barats,Walther Kuhn,H. Orfeuvre,Uwe Wagner,Barbara Richter,Hans-Joachim Lueck,Jacobus Pfisterer,SD Costa,W. Schroeder,Rainer Kimmig,Eric Pujade-Lauraine +16 more
TL;DR: Addition of epirubicin to TC did not improve survival or time to treatment failure in patients with advanced epithelial ovarian cancer; therefore, it cannot be recommended for clinical use in this population.
Journal ArticleDOI
Intense Dose-Dense Sequential Chemotherapy With Epirubicin, Paclitaxel, and Cyclophosphamide Compared With Conventionally Scheduled Chemotherapy in High-Risk Primary Breast Cancer: Mature Results of an AGO Phase III Study
Volker Moebus,Christian Jackisch,Hans-Joachim Lueck,Andreas du Bois,Christoph Thomssen,Christian M. Kurbacher,Walther Kuhn,Ulrike Nitz,Andreas Schneeweiss,Jens Huober,Nadia Harbeck,Gunter von Minckwitz,Ingo B. Runnebaum,Axel Hinke,Rolf Kreienberg,Gottfried E. Konecny,Michael Untch +16 more
TL;DR: IDD-ETC was less well tolerated compared with conventional chemotherapy but significantly improved event-free and overall survivals in patients with high-risk primary breast cancer who had four or more positive axillary lymph nodes.
Journal ArticleDOI
Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer in the APHINITY Trial: 6 Years' Follow-Up.
Martine Piccart,Marion Procter,Debora Fumagalli,Evandro de Azambuja,Emma Clark,Michael S. Ewer,Eleonora Restuccia,Guy Jerusalem,Susan Dent,Linda Reaby,Hervé Bonnefoi,Ian E. Krop,Tsang Wu Liu,Tadeusz Pienkowski,Masakazu Toi,Nicholas Wilcken,Nicholas Wilcken,Michael Andersson,Young-Hyuck Im,Ling Ming Tseng,Hans-Joachim Lueck,Marco Colleoni,Estefania Monturus,Mihaela Sicoe,Sebastien Guillaume,José Bines,Richard D. Gelber,Giuseppe Viale,Christoph Thomssen,Investigators +29 more
TL;DR: PURPOSEAPHINITY, at 45 months median follow-up, showed that pertuzumab added to adjuvant trastuzumaab and chemotherapy significantly improved invasive disease-free survival (IDFS) (hazard ratio 081).
Journal ArticleDOI
Sorafenib plus topotecan versus placebo plus topotecan for platinum-resistant ovarian cancer (TRIAS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial
Radoslav Chekerov,Felix Hilpert,Sven Mahner,Sven Mahner,Ahmed El-Balat,Philipp Harter,Nikolaus de Gregorio,Claudius Fridrich,Susanne Markmann,Jochem Potenberg,Ralf Lorenz,Guelten Oskay-Oezcelik,Marcus Schmidt,Petra Krabisch,Hans-Joachim Lueck,Rolf Richter,Elena Ioana Braicu,Andreas du Bois,Jalid Sehouli,Werner Lichtenegger,Isil Yalcinkaya,Marion Kittner,Ellen Konwert,Maren Keller,Alexander Mustea,Dominique Koensgen-Mustea,Klaus Pietzner,Oumar Camara,Pauline Wimberger,G. Elser,Sandra Polleis +30 more
TL;DR: Sorafenib, when given orally in combination with topotecan and continued as maintenance therapy, showed a statistically and clinically significant improvement in progression-free survival in women with platinum-resistant ovarian cancer.